Genta Incorporated Announces Webcast of 2010 Annual Shareholders Meeting
Datum : 11/06/2010 @ 14h10
Quelle : Business Wire
Name : Genta Incorporated (GETA)
Kurs : 0.0429 0.0 (0.00%) @ 13h50
Genta Incorporated Announces Webcast of 2010 Annual Shareholders Meeting
Genta Incorporated (OTCBB: GETA.OB) announced that the Company will host a conference call and live audio webcast of its 2010 Annual Meeting of Shareholders. The meeting will be held on Tuesday, June 15, 2010 at 9:00 am ET at The Madison Hotel in Morristown, NJ. Company management will present an overview of the Company?s research programs, clinical and regulatory strategies, and timelines.
Conference Call and Webcast Information:
Participants can access the live call by dialing (877) 634-8606 (U.S. and Canada) or (973) 200-3973 (International). The access code for the live call is Genta Incorporated. The call will also be webcast live at http://www.genta.com/investorrelation/events.html.
For investors unable to participate in the live call, a replay will be available approximately two hours after the completion of the call, and will be archived for 30 days. Access numbers for this replay are: (800) 642-1687 (U.S. and Canada) and (706) 645-9291 (International); conference ID number is: 77021779. Shareholders wishing to attend the meeting may call the hotel at 1-800-526-0729 for directions.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company?s research platform: DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genasense® is being developed as an agent that may enhance the effectiveness of anticancer therapy. The Company is currently collecting long-term followup data on durable response and overall survival from the recently completed randomized Phase 3 study of Genasense® in patients with advanced melanoma (the AGENDA trial). The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Genta has initiated a broad clinical program to evaluate the safety and efficacy of tesetaxel in patients with solid tumors. In the U.S., Genta is exclusively marketing Ganite® (gallium nitrate injection), which is indicated for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The Company has developed proprietary oral formulations of the active ingredient in Ganite® that are being evaluated as potential treatments for diseases associated with accelerated bone loss. Ganite® and Genasense® are available on a ?named-patient? basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.
Safe Harbor
This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such forward-looking statements include those that express plan, anticipation, intent, contingency, goals, targets, or future developments and/or otherwise are not statements of historical fact. The words ?potentially?, ?anticipate?, ?could?, ?calls for?, and similar expressions also identify forward-looking statements. The Company does not undertake to update any forward-looking statements. Factors that could affect actual results include, without limitation, risks associated with:
the Company?s ability to obtain necessary regulatory approval for its product candidates from regulatory agencies, such as the U.S. Food and Drug Administration and the European Medicines Agency;
the safety and efficacy of the Company?s products or product candidates;
the commencement and completion of any clinical trials;
the Company?s assessment of its clinical trials;
the Company?s ability to develop, manufacture, license, or sell its products or product candidates;
the Company?s ability to enter into and successfully execute any license and collaborative agreements;
the adequacy of the Company?s capital resources and cash flow projections, or the Company?s ability to obtain sufficient financing to maintain the Company?s planned operations;
the adequacy of the Company?s patents and proprietary rights;
the impact of litigation that has been brought against the Company; and
the other risks described under Certain Risks and Uncertainties Related to the Company?s Business, as contained in the Company?s Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2009 and its most recent quarterly report on Form 10-Q.
http://ih.advfn.com/...mona&article=43195190&symbol=NB%5EGETA
|
Thread abonnieren
ETF-Sparplan